Buprenorphine Microdosing for Opioid Use Disorder
(Micro-bupe Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new approach to initiating treatment for individuals with opioid use disorder (OUD). Researchers compare a microdosing method, where patients begin with very low doses of buprenorphine (BUP) while continuing their current opioid use, to the usual method that requires patients to stop opioids and undergo withdrawal first. The goal is to determine if the microdosing method is easier or more effective. Individuals who misuse opioids, have chronic pain, and are currently taking opioids might be suitable candidates, particularly if they have a planned hospital stay of at least 48 hours. As a Phase 4 trial, this study involves an FDA-approved treatment and aims to understand how it can benefit more patients.
Do I have to stop taking my current medications for the trial?
If you are in the microdosing group, you can continue taking your current opioids. However, if you are in the treatment as usual group, you will need to stop taking other opioids and go through withdrawal before starting the trial medication.
What is the safety track record for these treatments?
Research has shown that buprenorphine, a medication often used to treat opioid addiction, is generally safe. One study found that buprenorphine is safer than methadone, another common treatment for opioid addiction, making it a popular choice in many countries, such as Australia.
Researchers are studying the microdose induction method for its safety and effectiveness. This method involves starting with very small doses of buprenorphine to help patients switch from their current opioids without experiencing withdrawal symptoms. In some studies, many patients successfully switched to buprenorphine using this approach.
Overall, buprenorphine, even in small starting doses, is usually well-tolerated. There are no widespread reports of serious side effects when starting at these lower doses. However, anyone considering joining a trial should discuss possible side effects with the trial team, who can provide the most current information and support.12345Why are researchers enthusiastic about this trial?
Researchers are excited about the Buprenorphine microdose induction protocol for opioid use disorder because it offers a new approach to transitioning patients onto Buprenorphine (BUP) without the typical withdrawal symptoms. Unlike the standard treatment, which often requires patients to stop opioids completely before starting BUP, this microdosing method allows for a smoother induction by gradually introducing the medication in small doses. This could potentially lead to higher treatment retention rates and greater overall success in managing opioid dependency.
What evidence suggests that this trial's treatments could be effective for opioid use disorder?
Research has shown that small doses of buprenorphine can effectively treat opioid addiction. In this trial, participants in the BUP microdose induction arm will follow a novel protocol to prevent withdrawal symptoms, easing the start of treatment. This approach avoids the discomfort often associated with stopping other opioids before beginning treatment. Additionally, buprenorphine is considered safer than methadone, another treatment option for opioid addiction. Overall, evidence suggests that buprenorphine microdosing offers a promising way to manage this condition.15678
Who Is on the Research Team?
Aaron Fox, MD
Principal Investigator
Montefiore Medical Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with opioid misuse or disorder and chronic pain, who are currently taking opioids and can speak English or Spanish. They must be hospitalized for at least 48 hours but not already in treatment for opioid use disorder, have severe alcohol or benzodiazepine use disorders, cancer-related pain, untreated severe mental illness, pregnancy, or inability to consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo a 5-day BUP microdose induction protocol or a 2-day standard induction protocol during hospitalization
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 1 week, 1 month, 3 months, and 6 months
Long-term follow-up
Participants are assessed for BUP retention in care and illicit opioid use
What Are the Treatments Tested in This Trial?
Interventions
- BUP microdose induction
- Linkage to outpatient BUP treatment
- TAU
Trial Overview
The study compares a new way of starting BUP (buprenorphine-naloxone) treatment without stopping other opioids first (BUP microdose induction) against the usual method where patients stop other opioids and go through withdrawal before starting BUP. Participants will be randomly assigned to one of these two approaches.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants in this arm will receive a novel BUP microdose induction protocol.
Participants in this arm will receive standard BUP induction protocol.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aaron D. Fox
Lead Sponsor
Montefiore Medical Center
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Weill Medical College of Cornell University
Collaborator
Wake Forest University
Collaborator
Citations
Randomized Trial of Buprenorphine Microdose Inductions ...
These data will allow investigators to assess whether BUP microdosing targets of engagement-opioid- and pain-related symptoms-mediate OUD outcomes. Exploratory ...
Buprenorphine Microdosing the “Bernese Method”: Patient ...
Buprenorphine is increasingly favored over methadone for treating opioid use disorder in Australia due to its superior safety profile.
Low-Dose Buprenorphine Initiation in Hospitalized Adults ...
Of the 72 low-dose buprenorphine initiations 50 (69.4%) were completed in the hospital, 9 (12.5%) transitioned to complete as an outpatient, and 13 (18.1%) were ...
The Pharmacology of Buprenorphine Microinduction for ...
Multiple studies have demonstrated that precipitated withdrawal during induction onto BUP occurs commonly, especially when it is preceded by ...
Systematic review on effectiveness of micro-induction ...
Micro-induction is a novel buprenorphine induction approach that seeks to avoid withdrawal and minimize precipitated withdrawal, both barriers to standard ...
Initiating buprenorphine to treat opioid use disorder without ...
In this updated review, 57 of the 59 included studies reported transition rates to buprenorphine. Of those 57 studies, 81% (451/555) of patients ...
NCT05644587 | Novel Induction to Buprenorphine/Naloxone
Primary outcomes include effectiveness and safety. Secondary outcomes include treatment retention, self-reported use of opioids during induction, return to ...
Safety of induction at standard doses of buprenorphine for ...
The purpose of this study was to evaluate the safety and efficacy of initiation of buprenorphine for inpatients with OUD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.